2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1653

Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term Maintenance Therapy
Abstract Number: 1716

Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis
Abstract Number: 1643

Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Abstract Number: 2261

Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus
Abstract Number: 2204

Overall Agreement Between Sjögrens’s Minor Salivary Gland Biopsy and 2002 and 2012 Classification Criteria
Abstract Number: 2685

Overall and Cause Specific Mortality in Patients with Systemic Lupus Erythematosus. A Meta-Analysis of Observational Studies
Abstract Number: 1939

Overexpression of Ankyrin Repeat Domain Containing Protein 1 Gene (ANKRD1) in Dermatomyositis Muscle Biopsies Is Correlated to Hypoxia and Perifascicular Atrophy
Abstract Number: 517

Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren’s Syndrome Patients and Mice
Abstract Number: 1608

Overweight and Obesity Increase Risk of Rheumatoid Arthritis in Women in a Large Prospective Study
Abstract Number: 1903

Oxidation of Urate to Allantoin by Myeloperoxidase in Gout
Abstract Number: 1077

p21 Promotes Inflammatory Arthritis Resolution by Facilitating Alternative Activation of Macrophages
Abstract Number: 1571

Pain and Fatigue in Adult Patients with Rheumatoid Arthritis – Associations with Demographic Factors, Disease Related Factors, Body Awareness, Emotional and Psychosocial Factors
Abstract Number: 2443

Pain and Function Outcomes in Systemic Lupus Erythematosus Hip and Knee Arthroplasty
Abstract Number: 866

Pain Is Associated with Telomere Shortening in Women with Fibromyalgia
Abstract Number: 962

Pain, Sleep Disturbance, and Depression Mediate the Association Between Body Mass Index and Fatigue in Fibromyalgia

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].